First Analysis Downgrades Pharmaceutical Product Development (PPDI) to Equal Weight
Tweet
Share
E-mailGet Alerts PPDI Hot Sheet
Price: $33.24 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Join SI Premium – FREE
First Analysis downgraded Pharmaceutical Product Development (NASDAQ: PPDI) from Overweight to Equal Weight, maintains price target of $36.00.
For more ratings news on Pharmaceutical Product Development click here and for the rating history of Pharmaceutical Product Development click here.
Shares of Pharmaceutical Product Development closed at $32.28 yesterday.
For more ratings news on Pharmaceutical Product Development click here and for the rating history of Pharmaceutical Product Development click here.
Shares of Pharmaceutical Product Development closed at $32.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Healthpeak Properties Inc (DOC) to Equalweight Citing Limited Upside for the Call
- Guggenheim Downgrades Nuvalent (NUVL) to Neutral
- Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
First AnalysisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
